Tokyo, July 26 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058593) titled 'Prospective Observational Study to Validate HER2 Detection Rates in Advanced Gastric Cancer' on July 25.
Study Type:
Observational
Primary Sponsor:
Institute - Kitasato university, school of medicine
Condition:
Condition - Advanced gastric cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To determine the concordance rate of HER2 positivity between HER2 positivity in patients undergoing endoscopic biopsy of advanced gastric cancer
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Endoscopic biopsy of a tumor suspected of advanced gastric cancer or diagnosed as advanced gastric cancer
Key exclusion criteria - 1.Biopsy at another hospital confirms a histopathological type other than adenocarcinoma.
2.Patients who are at high risk of bleeding or who are unable to withdraw antithrombotic drugs according to Criteria for Withdrawal of Antithrombotic Drugs in Gastrointestinal Endoscopy Practice.
3.Other patients deemed inappropriate for inclusion by the study investigator.
Target Size - 100
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2024 Year 05 Month 10 Day
Date of IRB - 2024 Year 08 Month 07 Day
Anticipated trial start date - 2025 Year 01 Month 20 Day
Last follow-up date - 2029 Year 08 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000064871
Disclaimer: Curated by HT Syndication.
